Aspen Trading Statement

APN – Aspen Pharmacare Holdings Limited – Trading statement
Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 1985/002935/06)
Share code: APN & ISIN: ZAE000066692

Trading statement

Aspen’s shareholders are hereby advised that diluted normalised headline earnings
per share from continuing operations, headline earnings per share (“HEPS”) and
earnings per share, for the 12 months ended 30 June 2012, are expected to exceed
those reported in the comparative period, ended 30 June 2011, by the following

Measure Range Notes
Diluted normalised HEPS from continuing operations 18% to 24% 1
HEPS 21% to 27%
Earnings per Share 4% to 10% 2


1. Diluted normalised HEPS from continuing operations comprises diluted HEPS
from continuing operations adjusted for transaction costs, restructure costs and
foreign exchange gains on transaction accounting.

2. The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year.

The financial results on which this trading announcement is based have not been
reviewed or reported on by Aspen`s external auditors.
Aspen`s audited results for the year ended 30 June 2012 are scheduled to be
published on SENS on 12 September 2012.

30 August 2012

Sponsor: Investec Bank Limited










Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.